Abstract: Novel preventive treatment for COVID 19 and therapeutic treatment for early stages of COVID 19 or any other disease caused by SARS CoV 2. Pharmaceutical formulations and devices are disclosed to be able to implement these treatments. These treatments to prevent and alleviate the symptoms at early stages of COVID 19, the pandemic disease caused by SARS CoV 2. These treatments are based on the administration the nasal cavity and/or the lungs of solutions containing iota Carrageenan with or without the addition of xylitol as antiviral drug substances.

Abstract: The reduction in the sol-gel temperature of aqueous poloxamer surfactant compositions by the addition of hydrophobic vicinal diols is provided. Lowering of the sol-gel temperature and the gelling efficiency of water-soluble poloxamer block copolymers of polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide has been markedly improved by the addition of small amounts of at least one hydrophobic vicinal diol, such as monoalkyl glycols, monoalkyl glycerols, or monoacyl glycerols. The decrease in the sol-gel temperature facilitates gel formation, and such gels exhibit greater residence time on a surface, particularly those with biological properties.

Abstract: A shelf-stable concentrated antimicrobial composition and method of using same comprises: at least one cyclic carboxylic acid and/or salt thereof in an amount from about 1 wt. % to about 10 wt. %; at least one anionic surfactant in an amount from about 10 wt. % to about 35 wt. %; at least one non-surfactant strong acid having a pKa less than about 2.3 in an amount from about 2 wt. % to about 25 wt. %; and at least one chelating agent in an amount from about 0.1 wt. % to about 10 wt. %. The composition retains at least 90% of its original antimicrobial efficacy after storage for at least five years at room temperature, and is substantially free of hydrogen peroxide, sources of hydrogen peroxide, parabens, aldehydes, aldehyde releasing agents, phenols, biguanides, peroxycarboxylic acids, quaternary ammonium compounds, chlorine compounds, enzymes, and etchants.

Abstract: The present invention provides processes for preparing soluble salts of inositol phosphate characterized by a low level of impurities. Processes for preparing soluble salts (e.g., alkali-metal or ammonium) of inositol phosphates (e.g., hexasodium or dodecasodium salts), and of inositol hexaphosphate in particular (e.g., Na6IP6 and Na12IP6), are described. Also provided are pharmaceutical compositions, methods of use, combination treatments, kits, and articles of manufacture comprising soluble salts of inositol phosphates prepared according to the method of the invention.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes ectoine or an ophthalmologically acceptable ectoine derivative. The aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.

Abstract: The invention relates to bar composition comprising minimum floor levels of C10 soap while minimizing ratio of unsaturated C18 soap to caprate. Such bars provide enhanced rapid, antibacterial activity. Disclosed is a soap bar composition comprising: a) 25 to 85%, preferably 35 to 75% by weight of C8 to C24 fatty acid soap comprising: (i) C10 soap at 8% or 15% or greater, more preferably 16 to 32% by weight of total bar composition; and, (ii) unsaturated C18 soap, wherein weight ratio of said unsaturated C18 soap to C10 (caprate) soap is 1.2 to 0.1. b) 1 to 45% organic and inorganic adjuvant materials by weight of the composition; and, c) 5 to 30%, preferably 13 to 28% water by weight of the composition, wherein excess of C10 soap to unsaturated C18 soap is at least 6%.

Abstract: Disclosed are processes for the production of composition comprising one or more fructose amino acids, and related. Such a process may comprise the steps of: (a) providing plant material derived from a botanical source selected from plants of the families Solanaceae, Compositae, Asteraceae, Guttiferae, Umbelliferae, Papaveraceae, Vitidaceae or Acanthaceae; (b) extracting one or more fructose amino acid(s) from said plant material; and optionally, (c) detecting the presence and/or measuring the amount of said fructose amino acid(s) in the extract of step (b).

Abstract: A cardiomyocyte maturation medium comprises a base medium, one or more fatty acids such as palmitic acid, glucose and albumin. The one or more fatty acids and glucose are ideally present at a concentration ratio of about 1:10. Typically, the medium does not comprise TGF or insulin, or comprises minimal TGF and/or insulin. A cell culture vessel is provided that comprises opposed poles that facilitate force measurements of developing cardiac muscle.

Abstract: An application member includes a stimuli-responsive polymer that reversibly changes to being hydrophilic and to being hydrophobic in response to an external stimulus to allow impregnation and release of an active ingredient to be applied to the skin.

Abstract: Provided are a novel pseudoceramide compound and uses thereof. The pseudoceramide has antioxidant, anti-inflammatory, skin whitening, and moisturizing effects. In addition, the pseudoceramide can be synthesized in a simple and economically advantageous manner and is free from problems associated with the preparation of cosmetic formulations resulting from low hydrophilicity, thus being suitable for use in cosmetic applications.

Abstract: The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example, maintaining or enhancing female lower reproductive tract (LRT) homeostasis and physiological function. In particular, topical compositions of this disclosure can be formulated for use as a freshening, menopausal, fertility, and/or perineal composition.

Abstract: The present invention provides a use of (2R,4R)-1,2,4-trihydroxy heptadec-16-yne or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or an enantiomer thereof in the preparation of a pharmaceutical composition for preventing or treating liver injury.

Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.

Abstract: An emulsifier in powder form for animal feeds is described. A process for preparing the animal feed is also described.

Abstract: Provided are: a composition having an excellent anti-norovirus effect; use of a theaflavin compound for the preparation of the composition; and a method for preventing infection with a norovirus using a theaflavin compound. A theaflavin compound is used as an active ingredient for preventing infection with a norovirus. The theaflavin compound is preferably used together with an alcohol. The theaflavin compound is preferably one or more members selected from the group consisting of theaflavin, theaflavin-3-O-gallate, theaflavin-3?-O-gallate and theaflavin-3,3?-O-digallate that are derived from tea components.

Abstract: Novel preventive treatment for COVID 19 and therapeutic treatment for early stages of COVID 19 or any other disease caused by SARS CoV 2. Pharmaceutical formulations and devices are disclosed to be able to implement these treatments. These treatments to prevent and alleviate the symptoms at early stages of COVID 19, the pandemic disease caused by SARS CoV 2. These treatments are based on the administration the nasal cavity and/or the lungs of solutions containing iota Carrageenan with or without the addition of xylitol as antiviral drug substances.

Abstract: A method of improving the health of a first group of young monogastric mammals, the first group of young monogastric mammals nursing from a first lactating monogastric mammal during a pre-weaning period, the method including feeding the first lactating monogastric mammal an effective amount of an animal feed during the pre-weaning period, and feeding the first lactating monogastric mammal an effective amount of sugar alcohol during the pre-weaning period.

Abstract: The present invention is directed to a hair growth agent for external use comprising chiro-inositol, which is provided as an excellent hair growth agent.

Abstract: An emulsifier in powder form for animal feeds is described. A process for preparing the animal feed is also described.

Abstract: An emulsifier in powder form for animal feeds is described. A process for preparing the animal feed is also described.

Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.

Abstract: The invention concerns a plant conditioning preparation comprising a (i) water based extract of plant A, especially belonging to the genus Urtica, (ii) an oil based extract of plant B, especially belonging to the genus Salix, and (iii) an emulsifier. The invention further comprises a process for the production of the said plant conditioning preparation and a method for using such a preparation. In addition, a plant conditioning preparation obtainable by said process as well as a method and a use of a plant conditioning preparation for enhancing the immune system of a plant are also disclosed.

Abstract: Natural haircare ingredient composition and haircare compositions containing such natural haircare ingredient compositions are provided. In one novel aspect, the natural hair ingredient composition is provided which comprises candida Krusei mediated bio-modification of marine organism and plants including bio-modified natural marine surfactants, three-dimensional molecular framework, and natural mineral salts. In one embodiment, the natural surfactants are produced from natural marine organisms such as brown algae, sea kelp, sponge, brown seaweeds, and red seaweeds by candida Krusei mediated bio-modification. In another novel aspect, a haircare composition comprises about 10% of the natural haircare ingredient composition, by weight of the haircare composition. In one novel aspect, Candida Krusei bio-modification process is used. Natural polymeric compounds in the marine plants are modified during the process resulting in three-dimensional molecular framework.

Abstract: The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.

Abstract: The present invention relates to a new vegetable-based composition for liquid to be vaporized in electronic cigarettes, comprising water and propylene glycol of vegetable origin and/or glycerol and/or nicotine and/or natural flavors.

Abstract: The invention relates to synergistically effective ternary antimicrobial mixtures.

Abstract: Process to prepare an aqueous composition comprising a non-ionic antibacterial compound having a ClogP above about 2, the process having the steps of: pre-mixing the non-ionic antibacterial compound having a ClogP above about 2 with an oil to prepare a premix having more than about 60% per weight of the premix of oil and of non-ionic antibacterial compound having a ClogP above about 2, mixing the premix with water to obtain an aqueous composition having more than about 50% per weight of water.

Abstract: An inventive composition including an amount of sugar or sugar alcohol, an amount of alkalizing agent, and an amount of vehicle; whereby the inventive composition is formulated for transdermal administration to alleviate one or more disorder symptoms, for example neurogenic pain, or to treat one or more disorders, for example neurogenic inflammation.

Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.

Abstract: The present invention relates to dietary compositions comprising reduced level of methionine, tryptophan, all amino acids, or protein, dietary compositions comprising glycerol as a substitute for monosaccharides, disaccharides, and polysaccharides, and hypocaloric or calorie free diets with reduced level of energy, carbohydrates, or protein. Also disclosed are methods of using these compositions and diets, as well as fasting, to protect subjects against chemotherapy, radiotherapy, oxidative stress, or aging.

Abstract: The invention relates to a cosmetic formulation containing solid particles having a mean particle size of 3 ?m to 20 ?m, characterized in that the particles contain to at least 95% by wt. native cellulose, obtained from plant fibres, the percentages by weight relating to the dry total particle weight.

Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.

Abstract: The invention relates to a composition comprising a oil-soluble high carbon polar modified polymer, a sugar silicone surfactant and a hyperbranched polyol.

Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.

Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.

Abstract: The present invention relates to a mixture, having a skin-tightening effect, which is made up of: 10 to 80% by weight of a polysaccharide, preferably of an alginate, having a molecular weight of less than 600,000 Daltons, preferably less than 400,000 Daltons and more preferably less than 200,000 Daltons, 15 to 75% by weight of a polyhydroxylated agent selected from sugars and their derivatives, particularly sugar esters and sugar, ethers, preferably sorbitol, 3 to 15% by weight of poly(vinyl alcohol) or polyvinylpyrrolidone, and 0 to 25% by weight of cellulose or of a derivative of cellulose, such as carboxymethylcellulose or hydroxymethylcellulose. The present invention also relates to cosmetic compositions which contain this mixture. These cosmetic compositions enable a mechanical smoothing of the surface of the skin to be obtained progressively with great comfort of use and enables a good fixing of make-up products.

Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.

Abstract: Provided is a hyaluronic acid production promoter and a melanin synthesis inhibitor. The hyaluronic acid production promoter and the melanin synthesis inhibitor of the present invention each contain soybean saponin as an active ingredient. The soybean saponin is preferably soybean saponin aglycone. The soybean saponin aglycone preferably includes soyasapogenol A and/or soyasapogenol B. The hyaluronic acid production promoter and the melanin synthesis inhibitor of the present invention are each administered transdermally or orally.

Abstract: The invention comprises a cosmetic and/or dermatological preparation based on water-in-oil emulsions, comprising at least two W/O emulsifiers and at least one oil having a spreadability value of more than 600 mm2/10 min.

Abstract: Cosmetic and/or dermatological preparations based on a water-in-oil emulsion comprising at least two W/O emulsifiers which differ in their HLB value up to a maximum of 1 lead to sensorily acceptable preparations and at the same stable W/O emulsions.

Abstract: A formulation containing xylitol is used in a variety of ways to inhibit the ability of microorganisms to adhere to mucus membranes in the lungs throat, bladder, colon, ears, skin and rectum, and subsequently infect the host. In this age of antibiotic resistant bacteria, xylitol is an inexpensive alternative, which does not create problematic resistant bacterial strains for E. coli, staph, strep and C diff.

Abstract: The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity.

Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.

Abstract: The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid. Administration of the C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols with vitamin D3 is indicated for conditions such as bone loss, weight gain and autoimmune diseases such as lupus and rheumatoid arthritis.

Abstract: Pesticides based on hydroxy-substituted hydrocarbyl compounds, particularly vicinal diols, are available to control arthropod ectoparasites such as Pediculus humanus, Dermatophagoides pteronyssinus, Musca domestica, the Blattidae, Blatella Germanica, and Periplaneta Americana, by introducing to the locus of an infestation of the pest, a composition containing as active ingredient a vicinal diol.

Abstract: The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth thereof and/or slow the loss thereof. According to said method, a cosmetic composition including at least one C7 sugar, or derivative from esterification of said sugar, is administered. The present invention finally relates to a method for cosmetic care of hair and/or eyelashes and/or nails.

Abstract: Micronutrient combination product, wherein the micronutrient combination product comprises zeaxanthin, lutein, zinc and copper.

Abstract: An aqueous teat dip composition includes significant amounts of glycerin and preferably ethanol and has a pH of at least 8.5. The aqueous teat dip composition can be provided by a method that involves delivering a basic concentrate to a site where dairy animals are located where the concentrate is mixed with water before the pH of the resulting solution is upwardly adjusted. The basic concentrate can be a byproduct of a biofuel refining process.

Abstract: Described herein are topical pain compositions comprising between 15 and 90% mannitol, for use in the treatment of pain, itch and other cutaneous nerve conditions. The resulting compositions may be in the form of creams, gels, lotions, ointments, foams, suppositories, and sprays.

Abstract: It was impossible to prepare a granular product composed only of fine erythritol powders by using conventional erythritol having a particle diameter on the order of 100 ?m. Spherical erythritol granules for direct compression obtained by granulating, drying, and sieving 100% erythritol ultrafine powders having an average particle diameter of from 0.4 ?m to 23 ?m while spraying ethanol alcohol thereon. In the present invention, pherical erythritol granules for direct compression are obtained by granulating, drying, and sieving 100% erythritol ultrafine powders having an average particle diameter of from 0.4 ?m to 23 ?m while spraying ethanol alcohol thereon.